While circulating markers such as complement fragments and interleukins have shown promise as indicators of disease activity in mouse models of AMD, few studies have quantitatively assessed their incremental predictive value beyond established genetic (e.g., CFH, ARMS2) or imaging biomarkers. The gene discussed is CFH; the disease is age-related macular degeneration.